|12 Months Ended|
Dec. 31, 2021
|Subsequent Events [Abstract]|
Note 14 – Subsequent Events
On March 3, 2022, the Company settled a case filed by Jeffrey Lions and Daniel Vallera and paid $0.4 million in full and final settlement (see Note 9).
The Company has entered into a sublease with Aimmune Therapeutics, Inc. for 4,500 square feet of office space located in Brisbane, CA having a commencement date of January 1, 2022 and maturing on June 30, 2024.
On February 11, 2022,shares of issuable common stock were converted into an equal number of shares of common stock.
No definition available.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef